BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37963244)

  • 1. Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy.
    Bangayan NJ; Wang L; Burton Sojo G; Noguchi M; Cheng D; Ta L; Gunn D; Mao Z; Liu S; Yin Q; Riedinger M; Li K; Wu AM; Stoyanova T; Witte ON
    Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2312374120. PubMed ID: 37963244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory CARs fail to protect from immediate T cell cytotoxicity.
    Funk MA; Heller G; Waidhofer-Söllner P; Leitner J; Steinberger P
    Mol Ther; 2024 Apr; 32(4):982-999. PubMed ID: 38384128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity.
    Bassan D; Weinberger L; Yi J; Kim T; Weist MR; Adams GB; Foord O; Chaim N; Tabak S; Bujanover N; Lopesco Y; Vucci K; Schnair C; Levy-Knafo L; Kendall RL; Calzone FJ; Sharbi-Yunger A
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor.
    Fei F; Rong L; Jiang N; Wayne AS; Xie J
    Mol Ther; 2022 Mar; 30(3):1215-1226. PubMed ID: 34801727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
    Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
    Front Immunol; 2020; 11():1704. PubMed ID: 32849600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
    Han X; Wang Y; Wei J; Han W
    J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor Design Today and Tomorrow.
    Boucher JC; Davila ML
    Cancer J; 2021 Mar-Apr 01; 27(2):92-97. PubMed ID: 33750067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
    Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
    Front Immunol; 2021; 12():638639. PubMed ID: 34177890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor T cells therapy in solid tumors.
    Rababah F; Alabduh T; Awawdeh A; Shatnawi T; Al-Shdaifat M; Ibdah E; Shatnawi S; AbuZetun Y; Helaly AM; Ghorab DS
    Clin Transl Oncol; 2023 Aug; 25(8):2279-2296. PubMed ID: 36853399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
    Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
    Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.
    Zhang Z; Liu C; Wang M; Sun R; Yang Z; Hua Z; Wu Y; Wu M; Wang H; Qiu W; Yin H; Yang M
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
    Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
    Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation.
    McComb S; Nguyen T; Shepherd A; Henry KA; Bloemberg D; Marcil A; Maclean S; Zafer A; Gilbert R; Gadoury C; Pon RA; Sulea T; Zhu Q; Weeratna RD
    Front Immunol; 2022; 13():864868. PubMed ID: 35935988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.
    Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer.
    Sayadmanesh A; Yekehfallah V; Valizadeh A; Abedelahi A; Shafaei H; Shanehbandi D; Basiri M; Baradaran B
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111093. PubMed ID: 37897950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.